A major contributor to this article appears to have a close connection with its subject. (March 2015) |
Granules India Limited is an Indian pharmaceutical manufacturing company based in Hyderabad, India. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and rest of the world markets. Granules India Limited entered CRAMS segment, which focuses on contract research and manufacturing.[1][2]
 | |
| Company type | Public |
|---|---|
| BSE: 532482 NSE: GRANULES | |
| Industry | Pharmaceuticals |
| Founded | 1984 |
| Founder | Mr. Krishna Prasad Chigurupati |
| Headquarters | Hyderabad, India |
Area served | Worldwide |
Key people | Krishna Prasad Chigurupati (CMD) Harsha Chigurupati (ED) Sandeep Neogi (CFO) GSR Prasad(COO) Priyanka Chigurupati (ED) |
| Products | Paracetamol, Ibuprofen, Methocarbamol, Metformin, Guaifenesin, etc. |
| Revenue | FY 2018–19 INR 2,279 Crore |
| FY 2018–19 INR 236 Crore | |
Number of employees | 2789 |
| Website | www.granulesindia.com |
History edit
Granules India was formed in 1984 as Triton Laboratories. Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.[3] Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.[citation needed] In 1987, Triton became the only Indian company aside from Dr. Reddy's Laboratories to export pharmaceutical products to the U.S.[citation needed]
Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.[citation needed] In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".[citation needed] In 1990, it opened its second manufacturing facility at Jeedimetla to produce multiple APIs.
In 1991,[4] management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.[5]
In 1995,[4] Granules became a public company, after having initial public offerings on the Bombay and Hyderabad Stock Exchanges.[6]
In 2013, Granules India acquires Auctus Pharma for Rs 120 crore.[7]
In 2016, Granules India commissioned a new state of the art manufacturing unit that hosts facilities for Oncology and High Potent APIs. This new plant is located in Visakhapatnam.
In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in Wuhan, China. Granules India Limited on announced its intention to divest its entire equity shareholding in Granules Biocause Pharmaceuticals Co. Ltd. by selling its stake to joint venture partner.[8]
Infrastructure edit
Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China. The company also has two research centres, at Hyderabad and Pune.
The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.[citation needed]
Granules commissioned the world's single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum. The plant received its US FDA approval within six months of commissioning.[citation needed]
See also edit
References edit
- ^ "Granules India signs deal with Matchland Pty Ltd".
- ^ "Granules India". Moneycontrol.com. 10 May 2007. Retrieved 10 December 2009.
- ^ "Triton Laboratories Ltd Company info".
- ^ a b "Granules India Limited – About Us – Milestones". Granulesindia.com. Archived from the original on 17 July 2010. Retrieved 30 September 2010.
- ^ "Granules ties up with GSK Healthcare R&D".
- ^ "Granules, Amneal Pharma get FDA nod". Business Standard. 2 August 2006. Retrieved 10 December 2009.
- ^ "Granules India acquires Auctus Pharma for Rs 120 crore". www.businesstoday.in. 5 November 2013. Retrieved 10 February 2020.
- ^ "Granules India takes stake in Chinese firm". In-pharmatechnologist.com. Retrieved 30 September 2010.